Breathomics can discriminate between anti IgE-treated and non-treated severe asthma adults

Santini, Giuseppe; DI CARLO, Stefano; Benso, Alfredo; Mores, Nadia; Brinkmann, Paul; Valente, Salvatore; Montuschi, Paolo; Macagno, Francesco; Politano, GIANFRANCO MICHELE MARIA; Wagener, Ariane H.; Bansal, Aruna T.; Knobel, Hugo H.; Vink, Anton J.; Rattray, Nicholas; Santonico, Marco; Pennazza, Giorgio; Wang, Yuanyue; Horvath, Ildiko; Djukanovic, Ratko; Polosa, Riccardo; Fowler, Stephen J.; Chanez, Pascal; Chung, Kian F.; Sterk, Peter J.; Montuschi, Paolo

PORTO @ Archivio Istituzionale della Ricerca

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

Rationale: Omalizumab, an anti-IgE monoclonal antibody, is indicated in adults with severe persistent allergic asthma. Exhaled molecular markers can provide phenotypic information in asthma. Objectives: Determine whether adults with severe asthma on omalizumab (anti-IgE+) have a different breathprint compared with those who were not on anti-IgE therapy (anti-IgE-) as assessed by eNoses and gas chromatography/mass spectrometry (GC/MS) (breathomics). Methods: This was a cross-sectional analysis of the U- BIOPRED adult cohort. Severe asthma was defined by IMI-criteria [Bel, Thorax 2011]. Anti-IgE+ patients were on a regular treatment with s.c. omalizumab (150-375 mg) every 2-4 weeks. Exhaled volatile compounds trapped on adsorption tubes were analysed by a centralized eNose platform (Owlstone Lonestar, two Cyranose 320, Comon Invent, Tor Vergata TEN), including a total of 190 sensors, and GC/MS. Recursive feature elimination (http://topepo.github.io/caret/rfe.html) was used for feature selection and random forests, more robust to overfitting, for classification. Results: 9 anti- IgE+ (females/males 2/7, age 52.6±16.3 years, mean±SD, 1/2/6 current/ex/nonsmokers, pre-bronchodilator FEV1 70.6±21.1% predicted value) and 30 anti-IgE- patients (18/12 females/males, age 53.2±14.2 years, 0/16/14 current/ex/nonsmokers, pre-bronchodilator FEV1 59.6±30.7% predicted value) were studied. Conclusions: Preliminary results suggest that breathomics can distinguish between anti-IgE+ and anti-IgE- severe asthma patients.

Titolo:	Breathomics can discriminate between anti IgE-treated and non-treated severe asthma adults
Autori:	Santini, Giuseppe DI CARLO, STEFANO BENSO, ALFREDO Mores, Nadia Brinkmann, Paul Valente, Salvatore MONTUSCHI, PAOLO Macagno, Francesco POLITANO, GIANFRANCO MICHELE MARIA Wagener, Ariane H. Bansal, Aruna T. Knobel, Hugo H. Vink, Anton J. Rattray, Nicholas Santonico, Marco Pennazza, Giorgio Wang, Yuanyue Horvath, Ildiko Djukanovic, Ratko Polosa, Riccardo Fowler, Stephen J. Chanez, Pascal Chung, Kian F. Sterk, Peter J. Montuschi, Paolo mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2015
Rivista:	EUROPEAN RESPIRATORY JOURNAL
Abstract:	Rationale: Omalizumab, an anti-IgE monoclonal antibody, is indicated in adults with severe persistent allergic asthma. Exhaled molecular markers can provide phenotypic information in asthma. Objectives: Determine whether adults with severe asthma on omalizumab (anti-IgE+) have a different breathprint compared with those who were not on anti-IgE therapy (anti-IgE-) as assessed by eNoses and gas chromatography/mass spectrometry (GC/MS) (breathomics). Methods: This was a cross-sectional analysis of the U- BIOPRED adult cohort. Severe asthma was defined by IMI-criteria [Bel, Thorax 2011]. Anti-IgE+ patients were on a regular treatment with s.c. omalizumab (150-375 mg) every 2-4 weeks. Exhaled volatile compounds trapped on adsorption tubes were analysed by a centralized eNose platform (Owlstone Lonestar, two Cyranose 320, Comon Invent, Tor Vergata TEN), including a total of 190 sensors, and GC/MS. Recursive feature elimination (http://topepo.github.io/caret/rfe.html) was used for feature selection and random forests, more robust to overfitting, for classification. Results: 9 anti- IgE+ (females/males 2/7, age 52.6±16.3 years, mean±SD, 1/2/6 current/ex/nonsmokers, pre-bronchodilator FEV1 70.6±21.1% predicted value) and 30 anti-IgE- patients (18/12 females/males, age 53.2±14.2 years, 0/16/14 current/ex/nonsmokers, pre-bronchodilator FEV1 59.6±30.7% predicted value) were studied. Conclusions: Preliminary results suggest that breathomics can distinguish between anti-IgE+ and anti-IgE- severe asthma patients.
Appare nelle tipologie:	1.5 Abstract in rivista

File in questo prodotto:

File	Descrizione	Tipologia	Licenza
1446537549036.pdf	Full abstract	3. Abstract	PUBBLICO - Tutti i diritti riservati	Visibile a tuttiVisualizza/Apri

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11583/2622355

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.